featured
Event-Free Survival by Residual Cancer Burden in Patients With Early-Stage TNBC Receiving Pembrolizumab Plus Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
Ann. Oncol 2024 Feb 16;[EPub Ahead of Print], L Pusztai, C Denkert, J O'Shaughnessy, J Cortes, R Dent, H McArthur, S Kümmel, J Bergh, YH Park, R Hui, N Harbeck, M Takahashi, M Untch, PA Fasching, F Cardoso, Y Zhu, W Pan, K Tryfonidis, P SchmidFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.